A1C Almanac

Main Page

Your Body Knows Before Your Lab Results Do: The Early Signs That Insulin Resistance Is Reversing

Posted

by

dr Karunia Valeriani Japar

Table of Contents
Category:

Insulin Resistance as a Reversible State

Insulin resistance is conventionally described as a largely asymptomatic metabolic disturbance that precedes the onset of overt hyperglycemia, type 2 diabetes, and cardiovascular disease, often evolving over many years before crossing diagnostic thresholds. Epidemiological data link chronic insulin resistance not only to diabetes and atherosclerotic events but also to frailty and accelerated cardiovascular aging, underscoring its role as an early driver of cardiometabolic rather than a late complication.

However, interventional and mechanistic studies increasingly indicate that the reversal of insulin resistance is neither silent nor confined to laboratory values: short-term lifestyle and meal-timing interventions can improve insulin sensitivity, glucose homeostasis, and b-cell responsiveness within weeks, often before substantial changes in body weight occur. In clinical practice, these physiological shifts frequently coincide with a recognizable constellation of patient-reported experiences such as easier fat loss, calmer appetite, reduced postprandial fatigue, and clearer cognition that emerge as tissues regain insulin responsiveness.

From a preventive and longevity-oriented perspective, these early subjective changes function as actionable feedback loops, signaling metabolic rejuvenation well before end-organ complications develop or traditional biomarkers normalize. Systematically capturing these “weird” but reproducible signals through structured history-taking and digital health tools could enrich risk stratification, reinforce behavior change, and enable clinicians to monitor trajectory of insulin sensitivity in real time, thereby shifting care from late disease management to proactive preservation of metabolic youth.

From Stuck to Responsive: Body Composition and Weight Dynamics

One of the earliest and most clinically salient changes patients experience when insulin resistance begins to improve is qualitative shift in weight dynamics: fat loss transitions from effortful and frustratingly slow to more spontaneous and sustained even with unchanged or reduced dietary vigilance. This phenomenon reflects the normalization of adipose tissue lipolysis and systemic fat oxidation pathways that, in states of chronic hyperinsulinemia, are biochemically suppressed and rendered metabolically inflexible [1,2,3,4].

Under physiological conditions, insulin powerfully inhibits lipolysis by suppressing hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) through the PI3K/Akt and mTORC1-mediated pathways, thereby restraining the release of free fatty acids from adipose tissue and promoting triglyceride storage. However, in insulin resistant states, particularly when visceral adipose tissue (VAT) is expanded, adipocyte insulin signaling becomes impaired, yet paradoxically, compensatory hyperinsulinemia persists, locking adipocytes into a chronic anti-lipolytic posture that favors fat accumulation and impairs fat mobilization. Visceral adipose tissue exhibits heightened inflammatory signaling, with insulin-resistant adipocytes producing monocyte chemoattractant protein 1 (MCP1), recruiting proinflammatory macrophages and further entrenching a state of metabolic inflexibility. This tissue-level inflammation and ceramide accumulation impair intracellular insulin signaling, perpetuating the inability to suppress lipogenesis or activate lipolysis appropriately [1,3,5,6,7,8,9].

When intervention such as dietary restriction, time-restricted feeding, increased physical activity, or combinations thereof successfully restore insulin sensitivity, several mechanistic shifts converge to unlock adipose fat stores. First, fasting and postprandial insulin levels decline, relieving the chronic suppression of HSL and ATGL, and permitting adipocyte lipolysis to resume at physiological rates. Second, reduced inflammatory signaling in visceral adipose tissue lowers MCP1 production and proinflammatory macrophage infiltration, restoring insulin receptor substrate signaling and normalizing glucose and lipid handling. Third, skeletal muscle regains the capacity to preferentially oxidize fat during fasting states, a key facet of “metabolic flexibility” which enhances whole-body energy expenditure from fat oxidation and supports sustained fat loss. Notably, interventions that combine weight loss with exercise yield the greatest improvements in fasting fat oxidation, which in turn independently predict the magnitude of improvement in insulin sensitivity, explaining up to 52% of the variance in insulin sensitivity gains [1,3,4,6,7,10,11,12,13,14].

Clinically, the therapeutic significance of even modest weight reduction is well documented: loss of 5% to 10 % of initial body weight, when sustained produces statistically significant and clinically meaningful improvements in fasting glucose, hemoglobin A1c, systolic and diastolic blood pressure, and lipid profiles, with glycemic benefits observed with as little as 2% to 5% weight loss. These laboratory improvements are achieved despite concurrent reductions in antidiabetic medications and are closely linked to reductions in hepatic and intramuscular ectopic fat, which are direct mediators of tissue-specific insulin resistance. Importantly, successful weight-loss maintainers individuals who have lost approximately 15% of body weight and sustained that loss for years, exhibit enhanced insulin sensitivity compared to BMI-matched controls with no weight-loss history, underscoring that the metabolic benefits of improved insulin sensitivity persist and even deepen with long-term weight maintenance [4,15,16,17].

From a patient-reported perspective, the subjective experience of this metabolic transition, stubborn weight that finally “moves,” hunger that feels manageable, and energy that feels more stable reflects the underlying restoration of adipocyte lipolysis, tissue fatty acid oxidation, and hormonal feedback, together constituting a shift from a metabolically “stuck” state to one of responsiveness and flexibility. These early changes often precede substantial alterations in laboratory markers and provide patients with tangible, motivating feedback that their efforts are translating into real metabolic repair [4,10,12,14,18].

Appetite, Cravings, and the return of “Normal” Hunger

Among the most clinically striking yet under-recognized changes accompanying improved insulin sensitivity is a profound qualitative shift in hunger and appetite regulation: patients describe fewer urgent cravings, reduced “food noise” (the constant, intrusive preoccupation with food), and a newfound sense of calm and control around eating. This subjective experience, often described as “weird” by those who have struggled for years with compulsive hunger, reflects the normalization of multiple intersecting physiological systems such as glycemic stability, satiety hormone signalling, and central appetite circuitry that are collectively dysregulated in insulin-resistant states [19,20,21,22,23].

Insulin resistance is mechanistically linked to disordered postprandial glucose dynamics, characterized by exaggerated glycemic excursions, inadequate first-phase insulin secretion, and compensatory second-phase hyperinsulinemia that drives reactive hypoglycemia 2 to 5 hours after carbohydrate ingestion. This reactive hypoglycemia, defined as postprandial plasma glucose ≤70 mg/dL (≤3.9 mmol/L), triggers counter-regulatory hormonal responses, including increased cortisol and appetite-stimulating neuropeptides, that drive intense hunger, cravings for high-glycemic foods, irritability, shakiness, and impulsive eating behaviours even shortly after previous meals. Epidemiologic data from individuals with binge eating disorder and food addiction show that reactive hypoglycemia frequency is significantly elevated, and that hypoglycemia episodes, symptomatic or subclinical reinforce pathological eating patterns by creating a self-perpetuating cycle: hyperinsulinemia promotes hypoglycemia, which intensifies craving and food-seeking, which in turn drives further consumption of high-glycemic foods and worsens insulin dynamics [24,25,26].

Central mechanisms further amplify these peripheral signals. Circulating glucose levels exert direct, bidirectional control over prefrontal cortical and mesolimbic reward pathways: when glucose transiently declines, even within a physiologically “normal” range, from 88 to 67 mg/dL, activation of prefrontal executive control regions diminishes, while activation of the striatum, insula, and hypothalamus increases, accompanied by heightened desire for high-calorie, palatable foods and reduced inhibitory control over feeding behavior. This implies that modest postprandial glucose decrements, which are common in insulin-resistant individuals with delayed and excessive insulin secretion, promote overeating by tipping the neural balance away from cognitive restraint and toward impulsive reward-seeking [27,28].

Insulin resistance also disrupts the leptin-ghrelin axis, the primary hormonal system governing appetite and energy homeostasis. Leptin, secreted by adipocytes, normally signals energy sufficiency to hypothalamic neurons, suppressing appetite and increasing energy expenditure via STAT3-mediated upregulation of pro-opiomelanocortin (POMC) and downregulation of neuropeptide Y (NPY). However, in obesity and insulin resistance, a state of “leptin resistance” develops: despite elevated circulating leptin, appetite suppression fails, hunger remains high, and energy expenditure does not increase appropriately. Conversely, ghrelin, the “hunger hormone” secreted by the stomach before meals I inappropriately dysregulated in insulin-resistant states; while ghrelin levels may decline in chronic obesity, its receptor (GHS-R1a) expression in the hypothalamus is downregulated by both low ghrelin and high leptin, impairing physiological hunger-satiety cycling. Critically, serum ghrelin correlates negatively with insulin resistance and insulin levels, and serum leptin positively correlates with insulin resistance, together creating a hormonal profile that favours persistent hunger, metabolic inflexibility, and food-seeking despite abundant energy stores [19,23,29,30].

As insulin sensitivity recovers through lifestyle intervention, time-restricted feeding, weight loss, or pharmacologic therapy, several converging physiological changes restore “normal” hunger regulation. First, stabilization of postprandial glucose dynamics, characterized by flattening of glucose excursions, reduced insulin peaks and elimination of reactive hypoglycemia removes the metabolic trigger for compensatory hunger and high-calorie food cravings. Second, improvements in leptin sensitivity allow circulating leptin to appropriately suppress appetite and restore satiety signalling, even before substantial weight loss occurs. Third, dietary modifications, particularly reduced intake of rapidly digested carbohydrates and adoption of low-carbohydrate or intermittent fasting regimens have been shown to reduce overall food cravings, appetite, and hedonic hunger (the desire to eat for pleasure rather than energy need) independent of body weight changes [30,31,32,33,34,35,36].

The clinical phenomenology of these changes is often vivid: patients report feeling satisfied after smaller meals, forgetting about food between eating occasions, experiencing reduced urgency when hungry, and no longer feeling compelled to finish highly palatable foods like desserts. This reduction in “food noise”, the persistent, intrusive, and cognitively burdensome thoughts about food that characterize dysregulated appetite represents a normalization of food cue reactivity and a restoration of executive control over eating behaviour. Importantly, these subjective shifts often emerge within weeks of metabolic intervention and can precede substantial changes in body weight or laboratory markers such as hemoglobin A1c, making them valuable early behavioural biomarkers of improving insulin sensitivity and metabolic health. From a preventive and longevity-focused perspective, recognizing and validating these “weird” but reproducible experiences can enhance patient engagement, reinforce adherence, and provide real-time feedback on the effectiveness of therapeutic interventions targeting insulin resistance [21,22,33,34,36].

Energy, Circadian Rhythm, and Post-Meal Fatigue

Among the most subjectively prominent yet clinically underexplored signals of improving insulin sensitivity is a reorganization of daily energy patterns, characterized by reduced postprandial fatigue, elimination of mid-afternoon “crashes,” and stabilization of circadian energy availability. Patients frequently describe a qualitative shift from volatile, roller-coaster energy, punctuated by intense sleepiness after meals, reliance on caffeine or sugar to stay functional, and a paradoxical “wired-and-tired” state at night to a smooth, sustained vitality curve that allows sustained cognitive work, eliminates compulsive napping, and improves perceived sleep quality despite unchanged total sleep duration. These experiential changes, while subjective, align closely with emerging data linking glycemic stability, mitochondrial efficiency, and metabolic flexibility to enhanced daytime functioning and cognitive performance [37,38,39,40,41,42,43].

The mechanistic basis for postprandial fatigue in insulin-resistant individuals centers on dysregulated glucose-insulin dynamics and their downstream effects on neurotransmitter metabolism, circadian biology, and cellular energy production. In early type 2 diabetes, impaired glucose tolerance, and prediabetic states, the characteristic loss of first-phase insulin secretion causes an initial exaggerated postprandial glucose excursion, which then triggers a compensatory, delayed, and excessive second-phase insulin response occurring 2 to 5 hours after carbohydrate ingestion. This late hyperinsulinemia drives reactive hypoglycemia, a postprandial glucose nadir £70 mg/dL (£3.9mmol/L) which provokes counter-regulatory hormonal cascades involving cortisol, catecholamines, and growth hormone, and manifests symptomatically as tiredness, cognitive fog, irritability, shakiness, and a powerful drive to consume additional high-glycemic foods to restore energy. Even modest glucose declines from 88 to 67 mg/dL within the physiologically “normal” range reduce prefrontal executive control and increase limbic reward activation, impairing cognitive control and promoting impulsive food-seeking behavior. Insulin itself directly enhances Na+/K+-ATPase activity, which transiently hyperpolarizes neurons and can contribute to postprandial somnolence, particularly when combined with the tryptophan influx triggered by high insulin levels, which elevates central serotonin and melatonin synthesis [27,38,44,45,46].

Glycemic variability, the magnitude and frequency of glucose fluctuations throughout the day is independently associated with fatigue severity, sleep disturbances, and impaired quality of life in individuals with type 2 diabetes. In a study of type 2 diabetes patients, both hypoglycemic and hyperglycemic episodes were significantly associated with total fatigue scores on the Multidimensional Fatigue Inventory, with hypoglycemia specifically linked to general/physical fatigue, mental fatigue, and reduced activity, while hyperglycemia correlated with general/physical fatigue. Poor sleep quality and shorter sleep duration, both independently and synergistically with glycemic instability, further exacerbate insulin resistance, glucose fluctuations, and perceived energy deficits, creating a vicious cycle wherein metabolic dysregulation and sleep-wake disturbances mutually reinforce each other. Real-time continuous glucose monitoring studies reveal that in adults with type 2 diabetes, circulating glucose levels are associated with fatigue particularly during afternoon, evening, and nighttime hours in women, though these associations are attenuated during morning hours, suggesting a time-of-day modulation of glucose-fatigue relationships [39,40,47,48].

The interface between insulin resistance, circadian rhythm disruption, and metabolic dysfunction extends beyond glycemic control to encompass fundamental disruptions in the timing and coordination of metabolic processes. Experimental circadian misalignment, imposing an 8.5-hour delay of sleep-wake and feeding cycles over several days doubles the reduction in insulin sensitivity and increases systemic inflammation (high-sensitivity C-reactive protein) more than twofold compared to sleep restriction alone, demonstrating that circadian disruption exerts intrinsic adverse metabolic effect independent of sleep deprivation. In children, adolescents, and young adults with circadian rhythm sleep-wake disorder, reduced total sleep time and increased stage N1 sleep (light, fragmented sleep) are independently associated with impaired glucose tolerance and hyperglycemia, with 25.8% of this population exhibiting impaired glucose tolerance. These findings underscore that disrupted circadian alignment, whether from shift work, irregular eating patterns, or intrinsic circadian disorders directly impairs insulin signalling, glucose disposal, β-cell function, and inflammatory tone, culminating in perceived fatigue, cognitive inefficiency, and increased diabetes risk [49,50].

As insulin sensitivity improves through behavioral interventions such as time-restricted eating, weight loss, increased physical activity, or pharmacologic therapy, multiple converging physiological adaptations restore energy homeostasis and eliminate postprandial crashes. Time-restricted eating (TRE) regimens, limiting food intake to a 10-hour daytime window for as little as 3 weeks significantly decrease 24-hour glucose levels, lower nocturnal and morning fating glucose, and increase time spent in normoglycemia from 12.2 to 15.1 hours per day, even in the absence of weight loss or improvements in peripheral insulin sensitivity measured by hyperinsulinemic-euglycemic clamp. These glycemic improvements, particularly the normalization of nocturnal glucose control and elimination of reactive hypoglycemia, remove the metabolic triggers for compensatory hunger, energy crashes, and cognitive fog. Daytime eating schedules, compared to delayed eating schedules, also promote superior weight loss and improvements in energy metabolism, further supporting the therapeutic alignment of feeding windows with endogenous circadian rhythms [51,52,53,54].

Figure 1. Time restrictive eating in adults with type 2 diabetes [51]

Restoration of metabolic flexibility, the capacity to appropriately switch between carbohydrate and lipid oxidation in response to nutrient availability is a central feature of improved insulin sensitivity and is tightly linked to mitochondrial function. Mitochondrial oxidative capacity, as measured by in vivo phosphorus magnetic resonance spectroscopy, is positively associated with metabolic flexibility, basal respiratory exchange ratio, and insulin-stimulated glucose disposal. Impaired mitochondrial function reduces the capacity for lipid oxidation in the fasted state and glucose oxidation in the fed state, contributing to lipid accumulation, lipotoxicity, and further insulin resistance. As insulin sensitivity recovers, mitochondrial biogenesis, oxidative phosphorylation efficiency, and substrate switching normalize, enabling the skeletal muscle, liver, and adipose tissue to appropriately mobilize and oxidize fuels according to physiological demand, thereby stabilizing circulating glucose and free fatty acids and eliminating the energy “swings” that drive postprandial fatigue [14,42,55,56].

Clinically, stable glycemic profiles characterized by low glycemic variability and prolonged time in range support superior cognitive performance, reduced fatigue, and enhanced mood. Low glycemic index meals, compared to high glycemic index meals, consistently improve working memory, selective attention, alternating attention, and information processing speed, particularly during the late postprandial period (2 to 4 hours after eating), when reactive hypoglycemia would otherwise impair executive function. Glycemic stability is especially critical for cognitively demanding tasks, and individuals with better glucose regulation exhibit superior cognitive performance across multiple domains, including verbal memory, vigilance, and sustained attention. Conversely, frequent and severe glycemic fluctuations disrupt glucose metabolism, dysregulate calcium homeostasis, induce oxidative stress and inflammatory responses, and promote accumulation of advanced glycation end products, all of which contribute to neurological impairment and cognitive fatigue [41,57,58].

From a patient-reported perspective, the transition from volatile to stable daily energy, manifested as the ability to work through the afternoon without napping, reduced reliance on caffeine or sugar to maintain alertness, elimination of the “wired-and-tired” evening phenotype, and waking more refreshed despite unchanged sleep duration reflects the restoration of glycemic stability, circadian alignment, and mitochondrial metabolic flexibility. These subjective shifts often emerge within weeks of metabolic intervention, preceding substantial changes in body weight or laboratory markers such as hemoglobin A1c, and serve as valuable early behavioural biomarkers of improving insulin sensitivity. For clinicians and health tech innovators focused on preventive medicine and longevity, recognizing and systematically capturing these “weird” but reproducible energy changes can enhance patient engagement, validate therapeutic efficacy in real time, and support the design of personalized interventions targeting metabolic rejuvenation at its earliest stages [39,42,43,53,58].

Mood, Cognition, and the Brain-Insulin Axis

The brain is a profoundly insulin-sensitive organ, and alterations in cerebral insulin signalling exert wide-ranging neurocognitive and emotional consequences that extend far beyond peripheral glucose regulation. In experimental models, brain-specific knockout of the insulin receptor induces age-related anxiety, depressive-like behaviours, mitochondrial dysfunction, aberrant monoamine oxidase (MAO) A and B expression, and increased dopamine turnover in the mesolimbic system effects that can be reversed by MAO inhibitors or tricyclic antidepressants, demonstrating a direct mechanistic link between central insulin resistance and behavioural disorders. These findings suggest that insulin resistance in the brain directly disrupts neurotransmitter homeostasis, mitochondrial energy metabolism, and emotional regulation through loss of insulin’s trophic effects on neuronal and glial cells [59,60].

In human populations, insulin resistance and type 2 diabetes are consistently associated with significant impairments across multiple cognitive domains, including executive function, attention, working memory, psychomotor speed, and particularly declarative memory, even in non-diabetic individuals with early metabolic dysfunction. Middle-aged adults with insulin resistance, assessed by HOMA-IR or QUICKI exhibit cognitive performance reductions similar to those observed in overt type 2 diabetes, with higher degrees of insulin resistance predicting worse executive function and declarative memory independent of body mass index, blood pressure, or lipid levels. Longitudinal studies further demonstrate that insulin resistance at baseline is associated with progressive cognitive decline over 6-year follow-up periods, particularly in memory domains, underscoring that cognitive deficits develop early in impaired glucose metabolism and precede clinical diabetes diagnosis [61,62,63,64,65].

The emotional and mood disturbances accompanying insulin resistance are equally prominent and bidirectional. Type 2 diabetes is associated with approximately 50% increased risk of major depression and anxiety disorders, with chronic hyperglycemia, HPA axis dysregulation, chronic systemic inflammation, and neurotransmitter dysregulation all contributing to depressive symptomatology. Chronic stress and depression trigger persistent activation of the hypothalamic-pituitary-adrenal (HPA) axis, leading to hypercortisolemia, which in turn increases hepatic gluconeogenesis, impairs insulin-mediated GLUT4 translocation, elevates portal and peripheral free fatty acids, and directly impairs neurogenesis in the hippocampus, a brain region critical for both mood regulation and memory. Neuroimaging studies reveal that individuals with type 2 diabetes and comorbid major depression exhibit significant cortical gray matter reductions in bilateral prefrontal areas, diminished hippocampal volume correlated with higher HbA1c levels, and altered functional connectivity in frontal and fronto-parietal networks that predict depressive symptom severity [66,67,68,69].

Mechanistically, brain insulin resistance promotes neuroinflammation, oxidative stress, and impaired neurotrophic signalling through multiple pathways. Dysregulated peripheral glucose metabolism drives systemic inflammation via lipopolysaccharide (LPS)-mediated pathways, which disrupt insulin signalling in both peripheral tissues and the central nervous system, creating a metabolic “disconnect” wherein neurons become resistant to insulin’s actions and are deprived of the glucose needed to fuel synaptic transmission and plasticity. Insulin resistance also impairs peroxisome proliferator-activated receptor (PPAR) signalling, exacerbates neuro-inflammation, increases astrogliosis, promotes oxidative stress, and accelerates amyloid-beta deposition and hyperphosphorylated tau pathology, creating a positive feedback loop wherein insulin resistance and neuro-inflammatory pathologies co-conspire to drive neurodegeneration. Emerging evidence further demonstrates that gut microbiota modulate neurobehavior through changes in brain insulin signalling: high-fat diet-induced obesity induces insulin resistance in the nucleus accumbens and amygdala, alongside depressive-like and anxiety-like behaviours, which are reversed by antibiotic-mediated gut microbiota modulation and are transferable to germ-free mice via fecal transplant [70,71].

As metabolic control improves through lifestyle interventions, pharmacologic therapies, or behavioural weight loss programs, patients frequently describe a constellation of neurobehavioral improvements, “clearer thinking,” enhanced focus, greater emotional stability, reduced irritability, and improved mood that emerge before substantial changes in body weight or laboratory markers. Exercise, in particular, has been shown to directly improve brain insulin sensitivity, with training sessions increasing the number of neuronal extracellular vesicles carrying proteins involved in insulin signalling (notably Akt) and demonstrating for the first time that exercise impacts insulin signalling from neuronal extracellular vesicles in relation to clinical improvements in blood sugar control. This work suggests that exercise may boost cognition and memory by enhancing the brain’s ability to respond to insulin, thereby protecting against cognitive decline and reducing dementia risk [60,72,73].

Figure 2. a novel mechanism, for promoting healthy cognitive function with exercise. Created with BioRender.com with permission. AD, Alzheimer’s disease; ROS, reactive oxygen species [60]

Insulin-resistant individuals who achieve improvements in insulin sensitivity, whether through weight loss, time-restricted eating, increased physical activity, or pharmacologic therapy exhibit superior cognitive performance, particularly in working memory, global cognitive function, and executive function, compared to those who remain insulin-resistant. Critically, insulin resistance rather than sole elevation of blood glucose predicts cognitive decline, specifically in the memory domain, in persons with prediabetes, suggesting that treatments targeting insulin sensitivity (such as PPAR-γ agonists, GLP-1 receptor agonists, or intranasal insulin) might postpone or prevent cognitive decline in patients with diabetes. Intensive lifestyle interventions that achieve 5% or more weight loss also produce long-term reductions in depression symptoms, decreased use of antidepressant medications, and improved health-related quality of life, with benefits mediated by improvements in cardiorespiratory fitness, glycemic control, and cardiovascular risk factors [62,70,74,75,76].

Mindfulness-based interventions (MBI) further illustrate the tight coupling between metabolic control and emotional health: meta-analyses of randomized controlled trials demonstrate that MBI can improve HbA1c by 0.25%, reduce diabetes-related distress, and produce moderate-to-large reductions in depression and stress in people with diabetes, with effects mediated through modulation of the HPA axis, cortisol levels, and stress pathways. Similarly, digital health diabetes management programs that integrate behavioural coaching, education, and self-management support produce clinically meaningful improvements in HbA1c alongside significant reductions in depressive and anxiety symptoms [74,77].

From a patient-reported perspective, the subjective experience of “clearer thinking,” more stable mood, reduced brain fog, and less reactive irritability reflects the normalization of central insulin signalling, reduction in neuroinflammation, stabilization of glucose delivery to the brain, and restoration of neurotransmitter homeostasis. These neurobehavioral improvements, while often dismissed as nonspecific, are in fact manifestations of restored metabolic and neurobiological health at the cellular level, and they can create a virtuous cycle: better mood and cognition reinforce adherence to health behaviours, which in turn further improve insulin sensitivity and metabolic control. For clinicians and health tech innovators in the longevity space, recognizing these “weird but welcome” changes as legitimate early biomarkers of improving brain insulin signalling offers an opportunity to expand therapeutic endpoints beyond glycemic metrics, systematically capture patient-reported neurocognitive outcomes, and personalize interventions targeting the brain-metabolic axis to preserve cognitive and emotional resilience across the lifespan [60,62,75,78].

Skin, Hormones, and other Peripheral Signals

Beyond weight, hunger, and mood, a constellation of peripheral changes can accompany the healing of insulin resistance, collectively underscoring that insulin is not simply a “sugar hormone” but a pleiotropic coordinator of multi-system physiology. These peripheral signals, ranging from visible cutaneous manifestations to reproductive endocrine disturbances and gastrointestinal symptoms often normalize in parallel with improvements in insulin sensitivity, providing patients with tangible, felt evidence of metabolic restoration that extends far beyond laboratory parameters [79,80,81,82,83].

Cutaneous manifestations of chronic hyperinsulinemia, particularly acanthosis nigricans (AN) and acrochordons (skin tags), serve as clinically accessible biomarkers of insulin resistance and metabolic syndrome. Acanthosis nigricans is characterized by thickened, velvety, hyperpigmented plaques most commonly affecting the neck, axillae, and intertriginous regions, resulting from compensatory hyperinsulinemia that drives elevated circulating insulin to interact with insulin-like growth factor-1 (IGF-1) receptors on keratinocytes and dermal fibroblasts, triggering proliferation and epidermal hyperplasia. The presence of acanthosis nigricans is independently associated with elevated HOMA-IR values, with mean HOMA-IR scores of 3.5 ± 1.9 in obese individuals with AN compared to 2.6 ± 0.9 in those without AN, and the intensity of AN correlates directly with the magnitude of insulin resistance. Similarly, multiple skin tags (more than five or eight lesions) are significantly associated with increased HOMA-IR, with each additional five skin tags independently predicting a 1.4-unit increase in HOMA-IR, and are more sensitive than AN in detecting early carbohydrate metabolism disturbances, though less specific. Clinically, as insulin levels decline with weight loss, dietary modification, or insulin-sensitizing therapy, patients often observe that AN lesions soften or regress, and skin tags may become less prominent, a visible, dermatologic signal on the neck, axillae, and flexural surfaces that metabolic risk is moving in a favourable direction [79,84,85,86,87,88].

In women with polycystic ovary syndrome (PCOS), insulin resistance plays a central, mechanistic role in the pathophysiology of reproductive and endocrine dysfunction, affecting approximately 75% of individuals with the disorder. Insulin resistance-induced hyperinsulinemia drives ovarian androgen synthesis through multiple pathways: insulin directly stimulates cytochrome P450c17α activity in theca cells, enhances luteinizing hormone (LH) receptor expression, suppresses hepatic sex hormone-binding globulin (SHBG) synthesis, thereby increasing free androgen levels and paradoxically maintains intact ovarian insulin sensitivity despite systemic peripheral insulin resistance, creating a state of “selective insulin resistance” wherein hyperinsulinemia preferentially amplifies ovarian androgen production. This reciprocal interaction among androgen excess, hyperinsulinemia, and reduced SHBG creates a self-perpetuating “vicious cycle” that exacerbates clinical manifestations: hyperandrogenism drives further insulin resistance through elevation of free fatty acids and modification of skeletal muscle composition, which in turn perpetuates hyperinsulinemia and worsens PCOS symptoms [89,90,91].

The clinical phenotypes of PCOS vary in severity, with phenotype A (hyperandrogenism, ovulatory dysfunction, polycystic ovarian morphology) exhibiting the highest mean HOMA-IR values and phenotype C (hyperandrogenism and polycystic ovaries without ovulatory dysfunction) showing the lowest, underscoring the phenotype-dependent nature of insulin resistance. Importantly, the degree of menstrual dysfunction specifically, the duration between menstrual cycles correlates positively with the severity of insulin resistance: women with oligomenorrhea (cycles ≥45 days or ≥6 weeks between vaginal bleeding) exhibit significantly higher HOMA-IR and elevated free androgen index (FAI) compared to those with more regular cycles, suggesting that clinically overt menstrual irregularity can serve as a valuable predictor of insulin resistance in PCOS. As insulin sensitivity improves through lifestyle interventions, weight loss, metformin therapy, or other insulin-sensitizing strategies, many women with PCOS experience restoration of more regular menstrual cycles, reduction in androgenic symptoms (hirsutism, acne, alopecia), normalization of ovulation, and improved fertility profiles, changes that reflect the normalization of ovarian insulin signalling and the interruption of the vicious cycle linking hyperinsulinemia and hyperandrogenism [83,90,91,92].

Gastrointestinal symptoms, particularly bloating, abdominal discomfort, and altered bowel regularity, are also increasingly recognized as peripheral manifestations of insulin resistance mediated through gut microbial dysbiosis and intestinal barrier dysfunction. Experimental models demonstrate that insulin resistance per se—independent of obesity drives early, rapid, and reversible intestinal dysbiosis characterized by a bloom of pro-inflammatory Proteobacteria, increased epithelial paracellular permeability, impaired cell-cell junction integrity, and collapse of Paneth cell antimicrobial defenses. This gut barrier dysfunction allows translocation of bacterial endotoxins such as lipopolysaccharides (LPS) into systemic circulation, triggering low-grade inflammation, elevated pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and further exacerbation of insulin resistance and metabolic dysfunction, creating a bidirectional pathogenic loop between gut dysbiosis and metabolic disease. Importantly, discontinuation of insulin resistance, whether through pharmacologic restoration of insulin signalling or lifestyle intervention sufficient to promptly and completely reverse gut dysbiosis, restore microbial balance, and normalize intestinal barrier integrity, underscoring that insulin signalling itself is an indispensable gatekeeper of gut health. Clinically, patients improving their insulin sensitivity often report reduced bloating, less abdominal discomfort, more predictable digestive responses to food, and fewer inflammatory flares, changes that reflect the normalization of gut microbial composition and epithelial barrier function [81,93,94].

Physical exercise tolerance and recovery also improve markedly with restored insulin sensitivity, reflecting enhanced skeletal muscle glucose uptake, mitochondrial oxidative capacity, metabolic flexibility, and reduced systemic inflammation. A single bout of moderate-intensity exercise can increase glucose uptake by at least 40%, with insulin sensitivity remaining elevated for 16 to 120 hours post-exercise due to increased GLUT4 transporter presence in plasma membranes and enhanced intracellular insulin signalling. Chronic exercise training, whether aerobic, resistance, or combined produces sustained improvements in insulin sensitivity, with high-intensity resistance exercise demonstrating particularly robust effects on insulin receptor phosphorylation, glucose disposal, and reduction in inflammatory cytokines such as IL-6 and TNF-α, which directly contribute to impaired insulin signalling. Recent mechanistic studies reveal that exercise acts on skeletal muscle at the molecular level by altering the phosphorylation status of hundreds of proteins involved in insulin signalling, with participants displaying up to fivefold variability in insulin action that is reduced substantially following physical activity, even in individuals with baseline insulin resistance. From a patient-reported perspective, individuals frequently describe better tolerance to exercise, faster recovery between sessions, reduced muscle soreness, and more predictable energy during physical activity as insulin sensitivity improves, changes that reflect improved mitochondrial efficiency, enhanced substrate switching (metabolic flexibility), and reduced inflammatory burden [95,96,97,98,99,100,101].

Collectively, these peripheral signals, visible skin changes, restoration of menstrual regularity and fertility, reduced gastrointestinal symptoms, and enhanced physical performance, highlight the systemic, multi-organ impact of improved insulin sensitivity. Insulin, far from being merely a regulator of glucose homeostasis, exerts profound pleiotropic effects on cellular proliferation, steroidogenesis, gut barrier integrity, inflammatory signalling, and energy metabolism across tissues. For clinicians and health tech innovators in the longevity and preventive medicine space, recognizing and systematically documenting these “weird” but reproducible peripheral changes can expand the definition of therapeutic response beyond glycemic and anthropometric markers, providing patients with tangible, multisystem feedback that reinforces adherence and validates the holistic benefits of metabolic rejuvenation [79,80,81,82,83].

Patient-Reported signals as Early Biomarkers in Preventive Care

From a preventive and longevity‑oriented perspective, patient‑reported changes such as quieter cravings, steadier energy, improved sleep, better mood, and softening of cutaneous markers are not trivial anecdotes but potential early biomarkers of improving insulin sensitivity that complement formal biochemical testing. Conventional markers, fasting glucose, oral glucose tolerance tests, and indices such as HOMA‑IR remain essential for diagnosis and risk stratification, yet lifestyle and digital health studies show that improvements in subjective well‑being, depressive symptoms, fatigue, and functional capacity often emerge before, or in excess of, changes in classical metabolic endpoints [79,81,83,102,103].

Integrating these patient‑reported outcomes into routine care and digital platforms offers a pragmatic way to detect therapeutic response earlier and sustain behaviour change. Structured questionnaires and standardized patient‑reported outcome measures (PROMs) have been successfully used to capture lifestyle‑related changes in quality of life, mental health, and daily functioning alongside metabolic parameters, while smartphone‑based programs and AI‑enhanced continuous glucose monitoring now provide real‑time feedback that links symptoms, behaviours, and glycemic responses. Digital interventions that combine app‑based tracking of diet, activity, and symptoms with personalized algorithm‑driven feedback improve glycemic fluctuations, time in range, and body weight, with higher engagement correlating with better metabolic outcomes, illustrating how making invisible glucose dynamics “felt” can strengthen adherence [102,104,105,106,107].

In practice, explicitly asking about “non‑scale victories”, such as reduced brain fog, fewer afternoon crashes, improved exercise tolerance, normalized cycles, or remission of acanthosis nigricans can be as important as tracking kilograms lost, because these qualitative wins often mirror improvements in glucose handling, lipids, blood pressure, and cardiorespiratory fitness even when weight change is modest. Emphasizing and documenting these signals shifts the focus from weight‑centric metrics to a broader health‑centred model, which has been shown to enhance motivation, engagement, and psychological well‑being while still improving cardiometabolic risk profiles. As AI‑enabled health tech matures, combining continuous physiological data (glucose, heart rate, sleep) with systematically captured patient‑reported outcomes will allow clinicians to treat these “weird” early sensations not as noise, but as actionable, personalized biomarkers of metabolic rejuvenation [79,103,104,105,106].

Reframing Healing as a Multisystem Experience

When insulin resistance begins to resolve, the process is rarely confined to a single organ system or to incremental shifts in laboratory parameters; rather, it unfolds as a multisystem experience that patients can feel long before it is fully quantified. The same biological mechanisms that normalize insulin signalling in liver, muscle, adipose tissue, and brain simultaneously modulate weight dynamics, appetite regulation, circadian energy patterns, mood, skin integrity, and reproductive function. In clinical narratives, this often appears as a recognisable cluster of “small victories”, previously resistant central adiposity beginning to recede, cravings quieting without conscious restriction, afternoon crashes disappearing, sleep feeling more restorative, and cognition becoming clearer and more stable.

These phenomena should not be dismissed as mere anecdote or placebo, because they reflect underlying improvements in metabolic flexibility, glycemic stability, neuroendocrine signalling, and inflammatory tone that are central to long‑term cardiometabolic and brain health. Subjective experiences, such as realizing that dessert can be left unfinished, noticing that workdays no longer require emergency caffeine, or observing that skin changes associated with hyperinsulinemia are softening, are lived expressions of more efficient glucose disposal, restored satiety hormone responsiveness, and recalibrated autonomic balance. In many individuals, these shifts arise weeks to months before substantial changes in weight, fasting glucose, or hemoglobin A1c, positioning them as potential early clinical signals that an intervention is biologically “taking hold.”

For clinicians and health tech innovators focused on prevention and longevity, systematically capturing these patient‑reported signals offers a way to expand the definition of therapeutic response beyond traditional biochemical endpoints. Structured symptom tracking, digital diaries, app‑based check‑ins, and AI‑driven pattern recognition can transform qualitative experiences into usable data streams, allowing early course corrections, more personalised lifestyle prescriptions, and reinforcement of behaviours that patients can immediately feel are beneficial. In this framing, “weird” improvements are not noise but a valuable, proximal feedback layer that bridges the gap between molecular change and long‑term outcomes.

Reframing the healing of insulin resistance as a multisystem, perceptible journey, rather than a silent, purely laboratory-defined shift also has implications for how we communicate with and motivate patients. Validating these experiences as legitimate markers of progress can strengthen therapeutic alliance, enhance adherence, and make prevention‑oriented care feel rewarding well before hard endpoints like diabetes incidence or cardiovascular events are affected. Ultimately, aligning clinical protocols, digital tools, and patient narratives around this multisystem perspective may support a new standard of metabolic care: one in which restoring “metabolic youthfulness” is tracked not only in numbers, but in how people live, feel, and function in their daily lives, long before disease becomes inevitable.

Reference

  1. Zhao J, Wu Y, Rong X, Zheng C, Guo J. Anti-Lipolysis Induced by Insulin in Diverse Pathophysiologic Conditions of Adipose Tissue [Internet]. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020. Available from: https://www.dovepress.com/anti-lipolysis-induced-by-insulin-in-diverse-pathophysiologic-conditio-peer-reviewed-fulltext-article-DMSO
  2. successful, long-term weight loss maintainers compared with matched controls with no weight loss history. Nutrition & Diabetes [Internet]. 2017 Jun;7(6):e282–2. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519190/
  3. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine reviews [Internet]. 2002;23(2):201–29. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11943743/
  4. Clamp LD, Hume DJ, Lambert EV, Kroff J. Enhanced insulin sensitivity in successful, long-term weight loss maintainers compared with matched controls with no weight loss history. Nutrition & Diabetes [Internet]. 2017 Jun;7(6):e282–2. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519190/
  5. Hudgins EC, Johnson EJ, Sabita Rokka, Kashyap B, Mahugu A, Nguyen T, et al. Inhibition of lipolysis in visceral adipose tissue from obese mice and humans prevents impairment of endothelial Kir2.1 channels. Channels [Internet]. 2025 Sep 25 [cited 2026 Feb 2];19(1):2564651–1. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12477883/
  6. Bensussen A, José Antonio Torres-Magallanes, Roces E. Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue. 2023 Mar 21;14.
  7. Shimobayashi M, Albert V, Woelnerhanssen B, Frei IC, Weissenberger D, Meyer-Gerspach AC, et al. Insulin resistance causes inflammation in adipose tissue. The Journal of Clinical Investigation [Internet]. 2018 Mar 12;128(4):1538–50. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873875/
  8. Kim JY, Nasr A, Tfayli H, Bacha F, Michaliszyn SF, Arslanian S. Increased Lipolysis, Diminished Adipose Tissue Insulin Sensitivity, and Impaired β-Cell Function Relative to Adipose Tissue Insulin Sensitivity in Obese Youth With Impaired Glucose Tolerance. Diabetes. 2017 Sep 8;66(12):3085–90.
  9. Chakrabarti P, Kim JY, Singh M, Shin YK ., Kim J, Kumbrink J, et al. Insulin Inhibits Lipolysis in Adipocytes via the Evolutionarily Conserved mTORC1-Egr1-ATGL-Mediated Pathway. Molecular and Cellular Biology [Internet]. 2013 Jul 15;33(18):3659–66. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753874/
  10. Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes. Cell Metabolism [Internet]. 2018 Jun;27(6):1212-1221.e3. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990470/
  11. Goodpaster BH, Katsiaras A, Kelley DE. Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes [Internet]. 2003 [cited 2019 Jun 2];52(9):2191–7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12941756
  12. Kelley DE. Skeletal muscle fat oxidation: timing and flexibility are everything. Journal of Clinical Investigation. 2005 Jul 1;115(7):1699–702.
  13. Schenk S, Harber MP, Shrivastava CR, Burant CF, Horowitz JF. Improved insulin sensitivity after weight loss and exercise training is mediated by a reduction in plasma fatty acid mobilization, not enhanced oxidative capacity. The Journal of Physiology. 2009 Oct 9;587(20):4949–61.
  14. Galgani JE, Moro C, Ravussin E. Metabolic flexibility and insulin resistance. American Journal of Physiology-Endocrinology and Metabolism. 2008 Nov;295(5):E1009–17.
  15. Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and over. Current Obesity Reports [Internet]. 2017 Apr 28;6(2):187–94. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5497590/
  16. Snel M, Jonker JT, Schoones J, Lamb H, de Roos A, Pijl H, et al. Ectopic Fat and Insulin Resistance: Pathophysiology and Effect of Diet and Lifestyle Interventions. International Journal of Endocrinology. 2012;2012:1–18.
  17. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes. Diabetes Care. 2011 May 18;34(7):1481–6.
  18. Guo L, Xi Y, Jin W, Yuan H, Qin G, Chen S, et al. A 5:2 Intermittent Fasting Meal Replacement Diet and Glycemic Control for Adults With Diabetes. JAMA network open. 2024 Jun 21;7(6):e2416786–6.
  19. Uma Vijayashankar, Rajalakshmi Ramashetty, Mahesh Rajeshekara, Vishwanath N, Anshu Kumar Yadav, Akila Prashant, et al. Leptin and ghrelin dynamics: Unraveling their influence on food intake, energy balance, and the pathophysiology of type 2 diabetes mellitus. Journal of Diabetes and Metabolic Disorders. 2024 Apr 18;23.
  20. Free B. The Online GP [Internet]. The Online GP. 2025. Available from: https://www.theonlinegp.com/blog/breaking-free-from-food-noise-the-science-behind-constant-food-thoughts-and-why-meal-planning-changes-everything
  21. Bettadapura S, Dowling K, Jablon K, Al-Humadi AW, le Roux CW. Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities. International Journal of Obesity [Internet]. 2024 Mar 7;1–9. Available from: https://www.nature.com/articles/s41366-024-01500-y#:~:text=The study showed a decreased
  22. Badulescu S, Badulescu S, Badulescu S, Badulescu S, Badulescu S, Badulescu S, et al. Glucagon-Like Peptide 1 Agonist and Effects on Reward Behaviour: A Systematic Review. Physiology & Behavior. 2024 Jun 1;283:114622–2.
  23. Yeung AY, Tadi P. Physiology, obesity neurohormonal appetite and satiety control [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555906/
  24. Rania M, Caroleo M, Elvira Anna Carbone, Ricchio M, Maria Chiara Pelle, Zaffina I, et al. Reactive hypoglycemia in binge eating disorder, food addiction, and the comorbid phenotype: unravelling the metabolic drive to disordered eating behaviours. Journal of eating disorders. 2023 Sep 19;11(1).
  25. How to Treat Reactive Hypoglycemia [Internet]. Cleveland Clinic. 2021. Available from: https://health.clevelandclinic.org/how-to-treat-reactive-hypoglycemia
  26. Altuntaş Y. Postprandial Reactive Hypoglycemia. Şişli Etfal Hastanesi tıp Bülteni [Internet]. 2019 Aug 28;53(3):215–20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192270/
  27. Page KA, Seo D, Belfort-DeAguiar R, Lacadie C, Dzuira J, Naik S, et al. Circulating glucose levels modulate neural control of desire for high-calorie foods in humans. Journal of Clinical Investigation. 2011 Oct 3;121(10):4161–9.
  28. Rizza RA. Pathogenesis of Fasting and Postprandial Hyperglycemia in Type 2 Diabetes: Implications for Therapy. Diabetes. 2010 Aug 12;59(11):2697–707.
  29. ZHANG S, ZHANG Q, ZHANG L, LI C, JIANG H. Expression of ghrelin and leptin during the development of type 2 diabetes mellitus in a rat model. Molecular Medicine Reports. 2012 Oct 25;7(1):223–8.
  30. Marino JS, Xu Y, Hill JW. Central insulin and leptin-mediated autonomic control of glucose homeostasis. Trends in Endocrinology & Metabolism [Internet]. 2011 Apr [cited 2019 Nov 23]; Available from: https://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760(11)00037-3
  31. Relationships between changes in leptin and insulin resistance levels in obese individuals following weight loss. The Kaohsiung Journal of Medical Sciences [Internet]. 2013 Aug 1 [cited 2021 Jan 18];29(8):436–43. Available from: https://www.sciencedirect.com/science/article/pii/S1607551X12003622
  32. Aukan MI, Brandsæter IØ, Skårvold S, Finlayson G, Nymo S, Coutinho S, et al. Changes in hedonic hunger and food reward after a similar weight loss induced by a very low‐energy diet or bariatric surgery. Obesity. 2022 Aug 31;30(10):1963–72.
  33. Bloemendaal L van, IJzerman RG, Kulve JS ten, Barkhof F, Konrad RJ, Drent ML, et al. GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans. Diabetes [Internet]. 2014 Dec 1;63(12):4186–96. Available from: https://diabetes.diabetesjournals.org/content/63/12/4186
  34. Knufinke M, Lebbing M, Mesnage R. Case Report: Sustained weight loss and glycemic control from repeated long-term fasting in type 2 diabetes. Frontiers in Clinical Diabetes and Healthcare. 2025 Aug 7;6.
  35. Liu A, Fan Z, Lu X, Wu Y, Zhao W, Lou X, et al. The characteristics of postprandial glycemic response patterns to white rice and glucose in healthy adults: Identifying subgroups by clustering analysis. Frontiers in Nutrition. 2022 Oct 31;9.
  36. Martin CK, Rosenbaum D, Han H, Geiselman PJ, Wyatt HR, Hill JO, et al. Change in Food Cravings, Food Preferences, and Appetite During a Low-Carbohydrate and Low-Fat Diet. Obesity. 2011 Oct;19(10):1963–70.
  37. Chong MC, Louise Y, Roux le, Roux le. Changes in Eating Behaviour During Treatment With Obesity Medications. Clinical Obesity [Internet]. 2025 Dec 19 [cited 2026 Jan 18];16(1):e70065–5. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12717437/?utm_source=chatgpt.com
  38. Wahied Khawar Balwan, Walied Khawar Balwan, Saba N. Postprandial Somnolence: A Comprehensive Analysis of the Food Coma Phenomenon. East African Scholars Journal of Medical Sciences. 2025 Dec 26;8(12):432–9.
  39. Satwika Arya Pratama, Kurniawan R, Chiu HY, Kuo HJ, Ekpor E, Kung PJ, et al. Glycemic fluctuations, fatigue, and sleep disturbances in type 2 diabetes during ramadan fasting: A cross-sectional study. PLoS ONE. 2025 Mar 5;20(3):e0312356–6.
  40. Fritschi C, Park C, Quinn L, Collins EG. Real-Time Associations Between Glucose Levels and Fatigue in Type 2 Diabetes: Sex and Time Effects. Biological Research For Nursing. 2020 Feb 3;22(2):197–204.
  41. Philippou E, Constantinou M. The Influence of Glycemic Index on Cognitive Functioning: A Systematic Review of the Evidence. Advances in Nutrition [Internet]. 2014 Jan 6;5(2):119–30. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951795/
  42. Smith RL, Soeters MR, Wüst RCI, Houtkooper RH. Metabolic Flexibility as an Adaptation to Energy Resources and Requirements in Health and Disease. Endocrine Reviews. 2018 Apr 24;39(4):489–517.
  43. Andriessen C, Fealy CE, Veelen A, van Beek SMM, Roumans KHM, Connell NJ, et al. Three weeks of time-restricted eating improves glucose homeostasis in adults with type 2 diabetes but does not improve insulin sensitivity: a randomised crossover trial. Diabetologia [Internet]. 2022 Oct 1;65(10):1710–20. Available from: https://pubmed.ncbi.nlm.nih.gov/35871650/
  44. Tsolmon Tsogbayar, MD. Why do I crash after eating carbs? [Internet]. SiPhox Health. 2025 [cited 2026 Feb 2]. Available from: https://siphoxhealth.com/articles/why-do-i-crash-after-eating-carbs
  45. Often felt increasingly sleepy after eating? Here’s why that afternoon-slump feels inevitable post-meals [Internet]. The Economic Times. Economic Times; 2025 [cited 2026 Feb 2]. Available from: https://economictimes.indiatimes.com/news/india/often-felt-increasingly-sleepy-after-eating-heres-why-that-afternoon-slump-feels-inevitable-post-meals/insulin-resistance-and-the-crash-cycle/slideshow/126140821.cms
  46. Altuntaş Y. Postprandial Reactive Hypoglycemia. Şişli Etfal Hastanesi tıp Bülteni [Internet]. 2019 Aug 28;53(3):215–20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192270/
  47. Cheng W, Chen H, Tian L, Ma Z, Cui X. Heart rate variability in different sleep stages is associated with metabolic function and glycemic control in type 2 diabetes mellitus. Frontiers in physiology. 2023 Apr 14;14.
  48. Yang Y, Zhao L, Li D, Xu F, Wang X, Lu C, et al. Association of sleep quality with glycemic variability assessed by flash glucose monitoring in patients with type 2 diabetes. Diabetology & Metabolic Syndrome. 2021 Sep 23;13(1).
  49. Leproult R, Holmbäck U, Van Cauter E. Circadian Misalignment Augments Markers of Insulin Resistance and Inflammation, Independently of Sleep Loss. Diabetes. 2014 Jan 23;63(6):1860–9.
  50. Toyoura M, Miike T, Tajima S, Matsuzawa S, Konishi Y. Inadequate sleep as a contributor to impaired glucose tolerance: A cross‐sectional study in children, adolescents, and young adults with circadian rhythm sleep‐wake disorder. Pediatric Diabetes. 2020 Mar 16;21(4):557–64.
  51. Andriessen C, Fealy CE, Veelen A, van Beek SMM, Roumans KHM, Connell NJ, et al. Three weeks of time-restricted eating improves glucose homeostasis in adults with type 2 diabetes but does not improve insulin sensitivity: a randomised crossover trial. Diabetologia [Internet]. 2022 Oct 1;65(10):1710–20. Available from: https://pubmed.ncbi.nlm.nih.gov/35871650/
  52. Allison KC, Hopkins CM, Ruggieri M, Spaeth AM, Ahima RS, Zhang Z, et al. Prolonged, Controlled Daytime versus Delayed Eating Impacts Weight and Metabolism. Current Biology. 2021 Feb;31(3):650-657.e3.
  53. Diabetes Distilled: Even short-term time-restricted eating improves glycaemic control – DiabetesontheNet [Internet]. DiabetesontheNet. 2022 [cited 2026 Feb 2]. Available from: https://diabetesonthenet.com/diabetes-primary-care/time-restricted-eating-glycaemic-control/
  54. Study on time restricted eating reveals limiting food intake to daytime shows promising beneficial metabolic effects in adults with type 2 diabetes – Diabetologia [Internet]. Diabetologia-journal.org. 2025 [cited 2026 Feb 2]. Available from: https://diabetologia-journal.org/2022/07/26/study-on-time-restricted-eating-reveals-limiting-food-intake-to-daytime-shows-promising-beneficial-metabolic-effects-in-adults-with-type-2-diabetes/
  55. van de Weijer T, Sparks LM, Phielix E, Meex RC, van Herpen NA, Hesselink MKC, et al. Relationships between Mitochondrial Function and Metabolic Flexibility in Type 2 Diabetes Mellitus. Stadler K, editor. PLoS ONE. 2013 Feb 13;8(2):e51648.
  56. Gambardella J, Lombardi A, Santulli G. Metabolic Flexibility of Mitochondria Plays a Key Role in Balancing Glucose and Fatty Acid Metabolism in the Diabetic Heart. Diabetes. 2020 Sep 15;69(10):2054–7.
  57. Yin J, Cheng L, Hong Y, Li Z, Li C, Ban X, et al. A Comprehensive Review of the Effects of Glycemic Carbohydrates on the Neurocognitive Functions Based on Gut Microenvironment Regulation and Glycemic Fluctuation Control. Nutrients [Internet]. 2023 Dec 12;15(24):5080. Available from: https://pubmed.ncbi.nlm.nih.gov/38140339/
  58. Arshad MT, Maqsood S, Altalhi R, Shamlan G, Mohamed Ahmed IA, Ikram A, et al. Role of Dietary Carbohydrates in Cognitive Function: A Review. Food Science & Nutrition. 2025 Jul;13(7).
  59. Kleinridders A, Cai W, Cappellucci L, Ghazarian A, Collins WR, Vienberg SG, et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proceedings of the National Academy of Sciences. 2015 Mar 2;112(11):3463–8.
  60. Malin SK, Stewart NR, Ude AA, Alderman BL. Brain insulin resistance and cognitive function: influence of exercise. Journal of applied physiology. 2022 Dec 1;133(6):1368–80.
  61. Bruehl H, Sweat V, Hassenstab J, Polyakov V, Convit A. Cognitive impairment in nondiabetic middle-aged and older adults is associated with insulin resistance. Journal of Clinical and Experimental Neuropsychology. 2009 Sep 30;32(5):487–93.
  62. Willmann C, Brockmann K, Wagner R, Kullmann S, Preissl H, Schnauder G, et al. Insulin sensitivity predicts cognitive decline in individuals with prediabetes. BMJ Open Diabetes Research & Care. 2020 Nov;8(2):e001741.
  63. Lee J, Kim J, An SJ. Association of diabetes risk with changes in memory, working memory, and processing speed among older adults. Frontiers in Psychology. 2024 Nov 12;15.
  64. Welcome To Zscaler Directory Authentication [Internet]. Diabetesjournals.org. 2026 [cited 2026 Feb 2]. Available from: https://diabetesjournals.org/care/article-abstract/41/8/1749/36385/Cognitive-Function-Deficits-Associated-With-Long?redirectedFrom=fulltext
  65. Cerebral Insulin Resistance in Gifted Individuals: Relationships between High Cognitive Ability and Cerebral Metabolic Alterations. Journal of Contemporary Clinical Practice [Internet]. 2025 Feb 14 [cited 2026 Feb 2];11:270–81. Available from: https://www.jccpractice.com/article/cerebral-insulin-resistance-in-gifted-individuals-relationships-between-high-cognitive-ability-and-cerebral-metabolic-alterations-339/
  66. Lyra e Silva N de M, Lam MP, Soares CN, Munoz DP, Milev R, De Felice FG. Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes. Frontiers in Psychiatry. 2019 Feb 14;10.
  67. Ali SY, Sadik MI, Seid AM, Mohammed AH, Yimam AA, Mekonin Meskelu Shegere, et al. Association of systemic immune inflammation index with depression among adult type 2 diabetic patients in a tertiary hospital, Ethiopia, 2022. Frontiers in Endocrinology. 2025 Feb 21;16.
  68. Fanelli G, Raschi E, Hafez G, Matura S, Schiweck C, Poluzzi E, et al. The interface of depression and diabetes: treatment considerations. Translational Psychiatry [Internet]. 2025 Jan 24;15(1). Available from: https://www.nature.com/articles/s41398-025-03234-5
  69. Awani Kumar Diwakar. Depression and Type 2 Diabetes: Dissecting the Causal Mechanisms. Sumatera Medical Journal. 2024 May 1;7(2):106–14.
  70. de la Monte SM. Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer’s Disease. Drugs. 2016 Dec 17;77(1):47–65.
  71. Soto M, Herzog C, Pacheco JA, Fujisaka S, Bullock K, Clish CB, et al. Gut microbiota modulate neurobehavior through changes in brain insulin sensitivity and metabolism. Molecular Psychiatry [Internet]. 2018 Jun 18;23(12):2287–301. Available from: https://www.nature.com/articles/s41380-018-0086-5
  72. zurowska. Exercise May Boost Brain Function by Enhancing Insulin Sensitivity [Internet]. European Medical Journal. EMJ; 2025. Available from: https://www.emjreviews.com/diabetes/news/exercise-may-boost-brain-function-by-enhancing-insulin-sensitivity/
  73. Exercise Improves Brain Function, Possibly Reducing Dementia Risk [Internet]. Rutgers.edu. 2025. Available from: https://www.rutgers.edu/news/exercise-improves-brain-function-possibly-reducing-dementia-risk
  74. Venkatesan A, Zimmermann G, Rawlings K, Ryan C, Voelker L, Edwards C. Improvements in Glycemic Control and Depressive Symptoms Among Adults With Type 2 Diabetes: Retrospective Study. JMIR Formative Research [Internet]. 2023 Jan 26 [cited 2023 Apr 15];7(1):e41880. Available from: https://formative.jmir.org/2023/1/e41880/
  75. Impact of Intensive Lifestyle Intervention on Depression and Health-Related Quality of Life in Type 2 Diabetes: The Look AHEAD Trial. Diabetes Care. 2014 May 22;37(6):1544–53.
  76. Gruber JR, Ruf A, Süß ED, Tariverdian S, Ahrens KF, Schiweck C, et al. Impact of Blood Glucose on Cognitive Function in Insulin resistance: Novel Insights from Ambulatory Assessment. Nutrition & Diabetes. 2024 Sep 11;14(1).
  77. Ni Y, Ma L, Li J. Effects of mindfulness‐based intervention on glycemic control and psychological outcomes in people with diabetes: A systematic review and meta‐analysis. Journal of Diabetes Investigation. 2020 Nov 22;12(6):1092–103.
  78. Ashenafi Kibret Sendekie, Liknaw Workie Limenh, Gizachew Kassahun Bizuneh, Asmamaw Emagn Kasahun, Wondm SA, Fasil Bayafers Tamene, et al. Psychological distress and its impact on glycemic control in patients with diabetes, Northwest Ethiopia. Frontiers in Medicine. 2025 Mar 26;12.
  79. Barbato MT, Criado PR, Silva AK da, Averbeck E, Guerine MB, Sá NB de. Association of acanthosis nigricans and skin tags with insulin resistance. Anais Brasileiros de Dermatologia [Internet]. 2012 Feb 1;87(1):97–104. Available from: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962012000100012
  80. Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. Frontiers in Endocrinology [Internet]. 2023 Mar 28;14:1149239. Available from: https://pubmed.ncbi.nlm.nih.gov/37056675/#:~:text=Insulin resistance (IR) plays a
  81. Dalale Gueddouri, Michèle Caüzac, Véronique Fauveau, Fadila Benhamed, Wafa Charifi, Beaudoin L, et al. Insulin resistance per se drives early and reversible dysbiosis-mediated gut barrier impairment and bactericidal dysfunction. Molecular Metabolism [Internet]. 2022 Mar 1 [cited 2023 Oct 31];57:101438–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814824/#:~:text=Independent of obesity%2C insulin resistance
  82. Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Frontiers in Endocrinology [Internet]. 2018 Nov 23;9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266510/
  83. Piotr Szkodziak, Sławomir Woźniak. Insulin resistance in polycystic ovary syndrome phenotypes and the vicious cycle model in its etiology. Scientific Reports. 2025 Nov 28;15(1):42649–9.
  84. Mayo Clinic. Acanthosis nigricans – Symptoms and causes [Internet]. Mayo Clinic. 2018. Available from: https://www.mayoclinic.org/diseases-conditions/acanthosis-nigricans/symptoms-causes/syc-20368983
  85. Singh S, Agrawal N, Vishwakarma A. Association of acanthosis nigricans and acrochordon with insulin resistance: A cross-sectional hospital-based study from North India. Indian Journal of Dermatology. 2020;65(2):112.
  86. Hermanns-L?? T, Scheen A, Pi??rard GE. Acanthosis Nigricans Associated with Insulin Resistance. American Journal of Clinical Dermatology. 2004;5(3):199–203.
  87. Maaran AT, Prathiba P. Acanthosis Nigricans and Skin Tags as Markers of Insulin Resistance in Non-Diabetic Obese Individuals. Journal of Evidence Based Medicine and Healthcare. 2020 Feb 5;7(6):270–4.
  88. González-Saldivar G, Rodríguez-Gutiérrez R, Ocampo-Candiani J, González-González JG, Gómez-Flores M. Skin Manifestations of Insulin Resistance: From a Biochemical Stance to a Clinical Diagnosis and Management. Dermatology and Therapy [Internet]. 2016 Dec 5;7(1):37–51. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336429/
  89. Piotr Szkodziak, Sławomir Woźniak. Insulin resistance in polycystic ovary syndrome phenotypes and the vicious cycle model in its etiology. Scientific Reports. 2025 Nov 28;15(1):42649–9.
  90. Purwar A, Nagpure S. Insulin resistance in polycystic ovarian syndrome. Cureus [Internet]. 2022 Oct 16;14(10). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665922/
  91. Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, et al. Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. International Journal of Reproductive Medicine [Internet]. 2014;2014:1–17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334071/
  92. Hussein K, Karami M. Association between insulin resistance and abnormal menstrual cycle in Saudi females with polycystic ovary syndrome. Saudi Pharmaceutical Journal. 2023 Apr;
  93. Singh R, Zogg H, Wei L, Bartlett A, Ghoshal UC, Rajender S, et al. Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders. Journal of Neurogastroenterology and Motility. 2020 Nov 9;27(1).
  94. Kasar GN, Rasal PB, Upaganlawar AB, Pagar DS, Surana KR, Mahajan SK, et al. Navigating dysbiosis: Insights into gut microbiota disruption and health outcomes Gaurav. Community Acquired Infection [Internet]. 2025 Jun 20;12. Available from: https://www.hksmp.com/journals/cai/article/view/778
  95. Mishra S. Effect of Physical activity on Insulin Resistance, Inflammation and Oxidative Stress in Diabetes Mellitus. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. 2013;7(8).
  96. Amador M, Meza CA, McAinch AJ, King GA, Covington JD, Bajpeyi S. Exercise-Induced Improvements in Insulin Sensitivity Are Not Attenuated by a Family History of Type 2 Diabetes. Frontiers in Endocrinology. 2020 Mar 13;11.
  97. Sjøgren K. Major study reveals how exercise improves insulin sensitivity and… [Internet]. Science News. 2025. Available from: https://sciencenews.dk/en/major-study-reveals-how-exercise-improves-insulin-sensitivity-and-action
  98. Kim BH, Rhyu HS. The effects of different exercise types on insulin resistance and inflammatory markers in overweight female wrestlers. Journal of Exercise Rehabilitation. 2025 Jun 25;21(3):159–66.
  99. Chomiuk T, Niezgoda N, Mamcarz A, Śliż D. Physical activity in metabolic syndrome. Frontiers in physiology [Internet]. 2024 Feb 19;15. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10910017/#:~:text=Inadequate energy balance resulting from
  100. Samudera WS, Efendi F, Indarwati R. Effect of Physical Exercise on Insulin Sensitivity and the Modifiable Cardiovascular Risk Factors of Patients with T2DM: A Systematic Review. Jurnal Ners [Internet]. 2020 Jul 7 [cited 2023 Jun 30];15(1Sp):518–30. Available from: https://e-journal.unair.ac.id/JNERS/article/view/20521
  101. Mora-Rodriguez R, Ortega JF, Ramirez-Jimenez M, Moreno-Cabañas A, Morales-Palomo F. Insulin sensitivity improvement with exercise training is mediated by body weight loss in subjects with metabolic syndrome. Diabetes & Metabolism. 2019 May;
  102. Pape LM, Adriaanse MC, Kol J, van Straten A, van Meijel B. Patient-reported outcomes of lifestyle interventions in patients with severe mental illness: a systematic review and meta-analysis. BMC Psychiatry. 2022 Apr 13;22(1).
  103. Saboya PP, Bodanese LC, Zimmermann PR, Gustavo A da S, Macagnan FE, Feoli AP, et al. Lifestyle Intervention on Metabolic Syndrome and its Impact on Quality of Life: A Randomized Controlled Trial. Arquivos Brasileiros de Cardiologia [Internet]. 2017 Jan 1;108(1):60–9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245849/#r18
  104. Veluvali A, Dehghani Zahedani A, Hosseinian A, Aghaeepour N, McLaughlin T, Woodward M, et al. Impact of digital health interventions on glycemic control and weight management. npj Digital Medicine [Internet]. 2025 Jan 9;8(1). Available from: https://www.nature.com/articles/s41746-025-01430-7
  105. Zahedani AD, Veluvali A, McLaughlin T, Aghaeepour N, Hosseinian A, Agarwal S, et al. Digital health application integrating wearable data and behavioral patterns improves metabolic health. npj Digital Medicine [Internet]. 2023 Nov 25;6(1):1–15. Available from: https://www.nature.com/articles/s41746-023-00956-y#Sec11
  106. Maida E, Caruso P, Bonavita S, Abbadessa G, Miele G, Longo M, et al. Digital Health in Diabetes Care: A Narrative Review from Monitoring to the Management of Systemic and Neurologic Complications. Journal of Clinical Medicine. 2025 Jun 14;14(12):4240.
  107. Kitazawa M, Takeda Y, Hatta M, Horikawa C, Sato T, Osawa T, et al. Lifestyle Intervention With Smartphone App and isCGM for People at High Risk of Type 2 Diabetes: Randomized Trial. The Journal of Clinical Endocrinology and Metabolism [Internet]. 2024 Mar 15;109(4):1060–70. Available from: https://pubmed.ncbi.nlm.nih.gov/37931069/

‌

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading